Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5526_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Contents
- •1.1 Introduction
- •1.2 Pathophysiology
- •1.3 Case Presentation
- •1.4 Case Discussion
- •1.5 Clinical Characteristics
- •1.6 Diagnostic Algorithm
- •1.8 Management
- •1.9 Conclusion
- •References
- •2.1 Introduction
- •2.2 Pathophysiology
- •2.3 Case Presentation
- •2.4 Case Discussion
- •2.5 Clinical Characteristics
- •1.7 Differential Diagnosis
- •2.6 Diagnostic Algorithm
- •2.7 Management
- •2.8 Conclusion
- •References
- •3.1 Introduction
- •3.2 Pathophysiology
- •3.3 Case Presentation
- •3.4 Case Discussion
- •3.5 Clinical Characteristics
- •3.6 Diagnostic Algorithm
- •3.7 Management
- •3.8 Conclusion
- •References
- •4.1 Introduction
- •4.2 Pathophysiology
- •4.3 Case Presentation
- •4.4 Case Discussion
- •4.6 Diagnostic Algorithm
- •4.7 Management
- •4.8 Conclusion
- •References
- •5.1 Introduction
- •5.2 Pathophysiology
- •5.3 Case Presentation
- •5.4 Case Discussion
- •5.5 Diagnostic Algorithm
- •5.6 Management
- •5.7 Conclusion
- •References
- •6.1 Introduction
- •6.2 Pathogenesis
- •6.3 Case Presentation
- •6.4 Case Discussion
- •6.5 Diagnostic Algorithm
- •6.6 Management
- •6.7 Conclusion
- •References
- •7.1 Introduction
- •7.2 Pathophysiology
- •7.3 Case Presentation
- •7.5 Differential Diagnosis
- •7.7 The Following Strategies Are Essential
- •7.7.1 Acute Symptom Relief
- •7.7.1.1 Pharmacological Treatment
- •7.7.2.1 Pharmacologic Prophylaxis
- •7.8 Conclusion
- •References
- •8.1 Introduction
- •8.3 Case Study
- •8.4 Case Discussion
- •8.5 Clinical Management
- •8.7 Diagnosis
- •8.8 Treatment
- •8.9 Conclusion
- •References
- •9.1 Introduction
- •9.2 Case Presentation
- •9.4 Diagnosis Algorithm
- •9.5 Secondary SUNCT
- •9.6 Management
- •9.8 Conclusion
- •References
- •10.1 Introduction
- •10.2 Pathophysiology
- •10.3 Case Presentation
- •10.4 Case Discussion
- •10.5 Clinical Characteristics
- •10.6 Diagnostic Algorithm
- •10.7 Management
- •10.8 Conclusion
- •References
- •11.1 Introduction
- •11.2 Pathophysiology
- •11.3 Case Presentation
- •11.4 Case Discussion
- •11.5 Clinical Characteristics
- •11.6 Diagnostic Algorithm
- •11.6.1 Step 1: Detailed Patient History
- •11.8 Management
- •11.9 Conclusions
- •12.2 Pathophysiology
- •12.3 Case Presentation
- •12.4 Case Discussion
- •12.6 Treatment
- •12.7 Conclusion
- •References
- •References
- •12.1 Introduction
- •13.1 Introduction
- •13.2 Pathophysiology
- •13.3 Case Presentation
- •13.4 Case Discussion
- •13.5 Clinical Characteristics
- •13.6 Diagnostic Algorithm
- •13.7 Management
- •13.8 Conclusion
- •References
- •14.1 Introduction
- •14.2 Pathophysiology
- •14.3 Case Presentation
- •14.3.1 Clinical Case 1
- •14.3.2 Clinical Case 2
- •14.4 Case Discussion
- •14.5 Clinical Characteristics
- •14.7 Treatment/Management
- •14.8 Conclusion
- •References
- •15.1 Introduction
- •15.2 Case Presentation
- •15.3 Case Discussion
- •15.4 Diagnostic Algorithm
- •15.5 Pathophysiology
- •15.6 Clinical Presentation
- •15.6.1 External-Compression Headache (ECH)
- •15.6.2 External-Traction Headache (ETH)
- •15.7 Management
- •15.7.1 Nonpharmacological Strategies
- •15.7.2 Pharmacological Strategies
- •15.7.3 Patient Education and Awareness
- •15.8 Conclusion
- •References
- •16.1 Introduction
- •16.2 Pathophysiology
- •16.3 Case Presentation
- •16.4 Case Discussion
- •16.6 Diagnostic Algorithm
- •16.7 Management
- •16.8 Conclusion
- •References
- •17.1 Introduction
- •17.2 Pathophysiology
- •17.3 Case Presentation
- •17.4 Case Discussion
- •17.5 Clinical Characteristics
- •17.6 Diagnosis
- •17.7 Differential Diagnosis
- •17.8 Treatment
- •17.9 Conclusion
- •References
- •18.1 Introduction
- •18.2 Pathophysiology
- •18.3 Case Presentation
- •18.4 Case Discussion
- •18.5 Clinical Presentation
- •18.6 Diagnosis
- •18.7 Differential Diagnosis
- •18.8 Treatment
- •18.9 Conclusion
- •References
- •19.1 Introduction
- •19.2 Pathophysiology
- •19.3 Case Presentation
- •19.4 Case Discussion
- •19.5 Diagnostic Approach
- •19.6 Management
- •19.7 Conclusion
- •References
- •20.1 Introduction
- •20.3 Case Report
- •20.4 Case Discussion
- •20.6 Clinical Presentation
- •20.7 Diagnostic Algorithm
- •20.8 Conclusion
- •References
- •21.1 Introduction
- •21.2 Case Presentation
- •21.3 Clinical Characteristics
- •21.4 Diagnosis
- •21.5 Treatment
- •References
- •22.1 Introduction
- •22.3 Case Presentation 1
- •22.4 Case Discussion
- •22.5 Case Presentation 2
- •22.6 Case Discussion 2
- •22.7 Clinical Characteristics
- •22.8 Diagnostic Workup
- •22.9 Treatment
- •22.10 Prognosis
- •References
- •23.1 Introduction
- •23.2 Pathophysiology
- •23.3 Case Presentation
- •23.4 Case Discussion
- •23.6 Diagnostic Algorithm
- •23.7 Management
- •23.8 Conclusion
- •References
- •24.1 Introduction
- •24.2 Case Presentation
- •24.3 Case Discussion
- •24.4 Pathophysiology
- •24.6 Clinical Characteristics
- •24.8 Treatment Approaches
- •24.10 Conclusion
- •References
- •25.1 Introduction
- •25.2 Case Presentation
- •25.3 Case Discussion
- •25.4 Conclusion
- •References
- •26.1 Introduction
- •26.2 Pathophysiology
- •26.3 Case Presentation
- •26.4 Case Discussion
- •26.5 Clinical Characteristics
- •26.6 Diagnostic Algorithm
- •26.7 Management
- •26.8 Conclusion
- •References
- •27.1 Introduction
- •27.2 Case Presentations
- •27.3 Clinical Characteristics
- •27.4 Discussion
- •27.5 Conclusion
- •References
- •28.1 Introduction
- •28.2 Case Presentation
- •28.3 Case Discussion
- •28.4 Clinical Characteristics
- •28.5 Diagnosis
- •28.6 Conclusion
- •28.7 Key Messages
- •References
- •29.1 Introduction
- •29.2 Pathophysiology
- •29.3 Case Presentation
- •29.4 Clinical Presentation
- •29.5 Diagnosis
- •29.6 Treatment
- •29.7 Conclusion
- •References
- •30.1 Introduction
- •30.2 Clinical Case
- •30.3 Clinical Presentation
- •30.4 Differential Diagnosis
- •30.5 Diagnosis
- •30.6 Treatment
- •30.7 Conclusion
- •References
- •31.1 Introduction
- •31.2 Pathophysiology
- •31.3 Case Presentation
- •31.4 Case Discussion
- •31.5 Clinical Presentation
- •31.7 Conclusion
- •References
- •32.1 Introduction
- •32.2 Pathophysiology
- •32.3 Case Presentation
- •32.4 Case Discussion
- •32.6 Diagnosis
- •32.7 Additional Diagnostic Evaluations
- •32.8 Apply ICHD-3 Diagnostic Criteria [9]
- •32.10 Management
- •32.11 Conclusion
- •References
- •33.1 Introduction
- •33.2 Pathophysiology
- •33.3 Case Presentation
- •33.4 Clinical Characteristics
- •33.5 Diagnostic Algorithm
- •33.6 Treatment
- •33.7 Conclusion
- •References
- •34.1 Introduction
- •34.2 Pathophysiology
- •34.3 Case Presentation
- •34.4 Case Discussion
- •34.6 Diagnostic Algorithm
- •34.7 Treatment
- •34.8 Conclusion
- •References
- •35.1 Introduction
- •35.3 Case Presentation
- •35.4 Case Discussion
- •35.7 Treatment
- •35.7.1 Oxygen Therapy (100% Oxygen)
- •35.8 Conclusion
- •References
- •36.1 Introduction
- •36.2 Pathophysiology
- •36.3 Case Presentation
- •36.5 Diagnostic Algorithm
- •36.6 Treatment
- •36.7 Conclusion
- •References
- •37.1 Introduction
- •37.2 Pathophysiology
- •37.3 Case Presentation
- •37.4 Headache Characteristics
- •37.5 Case Discussion
- •37.6 Treatment
- •37.7 Conclusion
- •References
- •38.1 Introduction
- •38.2 Pathophysiology
- •38.3 Case Presentation
- •38.4 Clinical Presentation
- •38.5 Diagnostic Algorithm
- •38.6 Treatment
- •38.7 Conclusion
- •References
- •39.1 Introduction
- •39.3 Case Presentation
- •39.4 Case Discussion
- •39.6 ICHD-3 Diagnostic Criteria [28]
- •39.6.1 Diagnostic Criteria
- •39.7 Diagnostic Algorithm
- •39.9 Conclusion
- •References
- •40.1 Introduction
- •40.3 Case Presentation
- •40.4 Case Discussion
- •40.5.1 Diagnostic Algorithm
- •40.6 Treatment
- •40.7 Conclusion
- •References
- •41.1 Introduction
- •41.3 Case Presentation
- •41.4 Clinical Presentation
- •41.5 Differential Diagnosis
- •41.6 Conclusion
- •41.7 Key Messages
- •References
- •42.1 Introduction
- •42.2 Pathophysiology
- •42.3 Case Presentation
- •42.5 Case Discussion
- •42.6 Clinical Presentation
- •42.7 Diagnostic Algorithm [9]
- •42.8 Preeclampsia
- •42.9 Eclampsia
- •42.10 Fetal Assessment
- •42.11 Treatment
- •42.12 Antihypertensive Management [8]
- •42.14 Conclusion
- •References
- •43.1 Introduction
- •43.2 Pathophysiology
- •43.3 Case Presentation
- •43.4 Case Discussion
- •43.5 Clinical Manifestations
- •43.6 Diagnosis
- •43.7 Treatment
- •43.8 Conclusion
- •References
- •44.1 Introduction
- •44.2 Pathophysiology
- •44.3 Case Presentation
- •44.4 Case Discussion
- •44.6 Diagnostic Approach
- •44.7 Management
- •44.8 Conclusion
- •References
- •45.1 Introduction
- •45.2 Pathophysiology
- •45.3 Case Presentation
- •45.6 Treatment
- •45.7 Conclusion
- •References
- •46.1 Introduction
- •46.2 Pathophysiology
- •46.3 Case Presentation
- •46.4 Clinical Characteristics
- •46.5 Differential Diagnosis
- •46.6 Treatment
- •46.7 Conclusion
- •References
- •47.1 Introduction
- •47.2 Pathophysiology
- •47.3 Case Presentation
- •47.4 Case Discussion
- •47.5 Clinical Presentations
- •47.6 Diagnostic Algorithm
- •47.7 Differential Diagnosis
- •47.8 Treatment
- •47.9 Conclusion
- •References
- •48.1 Introduction
- •48.2 Pathophysiology
- •48.3 Case Presentation
- •48.4 Case Discussion
- •48.5 Clinical Characteristics
- •48.7 Treatment
- •48.8 Conclusion
- •References
- •49.1 Introduction
- •49.2 Pathophysiology
- •49.3 Case Presentation
- •49.4 Clinical Presentation
- •49.5 Diagnosis
- •49.6 Treatment
- •49.7 Conclusion
- •References
- •50.1 Introduction
- •50.2 Pathophysiology
- •50.3 Case Presentation
- •50.4 Case Discussion
- •50.5 Clinical Characteristics
- •50.6 Diagnosis
- •50.7 Treatment
- •50.8 Conclusion
- •References
- •51.1 Introduction
- •51.2 Case Presentation
- •51.3 Clinical Characteristics
- •51.4 Diagnosis
- •51.5 Treatment
- •51.6 Conclusion
- •References
- •52.1 Introduction
- •52.2 Pathophysiology
- •52.3 Case Presentation
- •52.4 Case Discussion
- •52.5 Clinical Characteristics
- •52.6 Diagnosis
- •52.6.1 Cervicogenic Headache
- •52.6.2 Migraine
- •52.6.3 Neck Pain
- •52.6.4 Demyelinating Lesions
- •52.6.5 Cervical Myelitis
- •52.6.6 Occipital Allodynia
- •52.6.7 Cervical Muscle Spasms
- •52.7 Treatment
- •52.7.2 Acupuncture
- •52.7.3 Transcutaneous Electrical Nerve Stimulations (TENS)
- •52.8 Minimally Invasive Treatment
- •52.8.1 Nerve Blocks
- •52.8.2 Botulinum Toxin A
- •52.8.3 Radio Frequency
- •52.8.4 Occipital Nerve Stimulation
- •52.9 Surgical Treatments
- •52.10 Conclusions
- •References
- •53.1 Introduction
- •53.2 Pathophysiology
- •53.3 Characteristics of Pain
- •53.4 Case Presentation
- •53.5 Case Discussion
- •53.6 Clinical Characteristics
- •53.8 Treatment
- •53.9 Conclusion
- •References
- •54.1 Introduction
- •54.2 Pathophysiology
- •54.3 Case Presentation
- •54.4 Case Discussion
- •54.5 Clinical Characteristics
- •54.6 Diagnostic Algorithm
- •54.7 Management
- •54.8 Conclusion
- •References
- •55.1 Introduction
- •55.2 Pathophysiology
- •55.3 Case Presentation

30
A. Borrelli et al.
Additionally, TIA, by denition, lasts less than 24h; therefore, prolonged symptoms necessitate the exclusion of an infarction.
Neuroimaging is essential for conrming the diagnosis of infarction. As in other
forms of ischemic stroke, the choice of the most appropriate brain imaging technique depends on a multifactorial evaluation. MRI or CT with angiography is indicated to exclude atherosclerosis, arterial dissection, or vasospasm. The use of MRI
with DWI (diffusion weighted imaging) sequences may be benecial in the acute
phase, as it is the most sensitive within the rst 24h. Patients arriving at the emergency department in the rst few hours may benet from a CT or MRI with DWI
and uid-attenuated inversion recovery (FLAIR) sequences to be evaluated for
thrombolysis. However, to date, there is no literature on the use of thrombolysis for
this indication, as most patients present to the emergency department hours or even
days after symptom onset [19].
The diagnostic workup must include laboratory tests to rule out underlying
thrombophilia, such as PT, aPTT, Factor V Leiden, protein C and S activity levels,
MTHFR mutations, antithrombin III, antiphospholipid, anticardiolipin, and anti-β2
glycoprotein antibodies, lupus anticoagulant, and homocysteine levels. To exclude
cardiac embolism, echocardiography (preferably transesophageal) along with prolonged electrocardiographic monitoring or Holter electrocardiogram (ECG) is mandatory: these can exclude a right-to-left shunt (patent foramen ovale) or arrythmias
such as cardiac brillation [4].
Step 1: Clinical suspicion
• Identify key clinical characteristics
– History of migraine with aura, particularly in young females, but not
exclusively
– Episode resembling previous ones, but longer in duration (by denition,
more than 60 min), with the possible addition of the following
characteristics:
• Additional symptoms (from the onset or starting progressively)
• Greater intensity of the attack
Step 2: Diagnostic workup
• Perform brain imaging: CTA or MRA; MRI with DWI and FLAIR is func-
tional in the rst 24h
• Conrm infarction: Primarily in the posterior cerebrovascular territory, but
not exclusively
• Rule out vascular disease (atherosclerosis, arterial dissection, vasospasm)
• Assess hypercoagulability
– Laboratory tests: PT, aPTT, Factor V Leiden, protein C and S activity lev-
els, MTHFR mutations, antithrombin III, antiphospholipid, anticardiolipin, anti-β2 glycoprotein antibodies, lupus anticoagulant, and
homocysteine levels.

3 Migrainous Infarction
31
• Rule out cardiac embolism (cardiac brillation, right-to-left shunt)
– Transesophageal (preferred) or transthoracic echocardiography
– Prolonged ECG or Holter ECG
Consider genetic testing for rare causes of migraine and stroke when appropriate, such as CADASIL and MELAS
• Assess risk factors for stroke:
– Blood pression monitoring
– Laboratory testing for dyslipidemia and diabetes
– Oral contraception
– Smoking
3.7 Management
Antiplatelet therapy with aspirin or clopidogrel is advisable for the prevention of
recurrences [4]. Dual antiplatelet therapy has never been studied explicitly in
migrainous infarction. However, aspirin and clopidogrel are recommended by the
American Heart Association American Stroke Association (AHA/ASA) ASA
guidelines for minor non-cardioembolic ischemic stroke or high-risk TIA for a
maximum of 90days [40]. They may also be a plausible choice for non- cardioembolic
migrainous infarction.
Assessment of modiable cardiovascular risk factors is also essential. As already
pointed out, traditional risk factors such as diabetes, hypertension, and dyslipidemia
are less frequent (and possibly less signicant) compared to other young stroke
patients. At the same time, oral contraception and smoking are more important. Oral
contraception is currently contraindicated by the U.S.Medical Eligibility Criteria
for Contraceptive Use in patients with migraine with aura, and its discontinuation is
recommended [41].
Preventive therapy for migraine is generally advised after ischemic brain events.
Although an association between migraine frequency and stroke risk has been
observed [42], there is no consistent evidence that migraine prevention reduces the
risk of stroke [43]. A 19-year cohort study, however, showed that migraine patients
who are treated with a combination of two or more preventive medications have a
reduced risk of stroke when compared to patients using only one medication [44].
Further studies are needed to clarify the role of migraine prevention in the risk of
ischemic stroke. Calcium channel blockers may be a suitable preventive option for
patients with migraine and a history of stroke, due to their vasodilatory effects and
anti-ischemic properties, which are mediated by interactions with GABA-A
(gamma-aminobutyric acid) receptors in the brain. Melatonin, valproic acid, and
onabotulinumtoxinA can be considered safe alternatives.
Regarding acute treatments, extreme caution is advised when using triptans and
ergotamines in patients with prolonged aura, due to a potential increased risk of

32
A. Borrelli et al.
stroke [4]. Furthermore, triptans are currently contraindicated in patients with a history of cardiovascular ischemic events, including cerebral infarction.
Most patients have a favorable outcome, with either complete remission or minor
residual symptoms. However, some cases of permanent signicant disability have
been reported. To the best of our knowledge, only one fatal case has been reported
in the literature: a 57-year-old woman who was admitted for a headache of greater
intensity than usual, and whose evaluation revealed signs of vasospasm and multifocal infarcts in the occipital and insular cortices as well as in the deep white matter
[6]. However, this case does not appear to meet all the criteria for migrainous infarction [10], and may be more appropriately classied as a migraine-related stroke
with different characteristics.
Rates of complete recovery after migrainous infarction vary widely in the literature. Arboix etal. reported that 67% of their patients were symptom-free at discharge, after 9.75±6.2days [30]. In a Scandinavian cohort of 33 patients evaluated
after 3months, only 3 (9%) had complete remission, while 28 (85%) had residual
symptoms (including visual eld defects), and 2 (6%) had signicant disability—
these two cases involved brainstem infarcts, resulting in tetraparesis and cranial
nerve involvement [12]. Serrano etal. reported that 67% of patients with migrainerelated stroke had mild symptoms at discharge (modied Rankin Scale 0–2),
increasing to 71% at 90days and 80% at the end of follow-up (mean: 7.5years;
range: 12–240months) [17]. Further data and analyses are needed to better understand the prognostic factors and natural history of migrainous infarction.
3.8 Conclusion
Migrainous infarction is a rare ischemic complication of migraine with aura, dened
by strict diagnostic criteria. It represents a specic entity within the complex and
still largely unexplored relationship between migraine and stroke. Here, we presented an exemplary case along with a discussion of the main clinical and pathophysiological characteristics, including recommendations for diagnostic workup
and management. However, these considerations are limited by the current literature, which consists predominantly of case reports and a few case series, with inconsistent or unveriable adherence to ICHD-3 criteria. Moreover, based on current
knowledge, the distinction between migrainous infarction and migraine-related
stroke does not appear to inuence the diagnostic approach or management strategy.
References
1. Headache Classication Committee of the International Headache Society (IHS). The international classication of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
2. Hu X, Zhou Y, Zhao H, Peng C.Migraine and the risk of stroke: an updated meta-analysis of
prospective cohort studies. Neurol Sci. 2017;38(1):33–40.

3 Migrainous Infarction
3. Ravi V, Osouli Meinagh S, Bavarsad SR.Reviewing migraine-associated pathophysiology and
its impact on elevated stroke risk. Front Neurol. 2024;15:1435208.
4. Chiang CC, Chen SP.Migrainous infarction. In: Handbook of clinical neurology [Internet].
Elsevier; 2024 [cited 2024 Oct 1]. p.465–74. Available from: https://linkinghub.elsevier.com/
retrieve/pii/B9780128233573000215.
5. Tietjen GE, Khubchandani J. Vascular biomarkers in migraine. Cephalalgia.
2015;35(2):95–117.
6. Marshall N, Maclaurin WA, Koulouris G.MRA captures vasospasm in fatal migrainous infarction. Headache. 2007;47(2):280–3.
7. Decima D, Cavallo M, Leotta MR, Gaballo A.Migrainous infarction: association with vascular risk factors in a male subject. Neurol Sci. 2009;30(S1):145–6.
8. Tsai CF, Chen CC, Wang SC, Yip PK. Reversible vasospasm in migrainous infarction. J
Ultrasound Med. 2010;29(3):481–4.
9. Vinciguerra L, Cantone M, Lanza G, Bramanti A, Santalucia P, Puglisi V, etal. Migrainous infarction and cerebral vasospasm: case report and literature review. J Pain Res. 2019;12:2941–50.
10. Lebedeva ER, Gurary NM, Olesen J.Diagnosis of migrainous infarction: a case report and
analysis of previously published cases. Diagnostics. 2023;13(15):2502.
11. Tzoulis C, Naess H, Thomassen L.Migrainous cerebral infarction in a previously healthy
93-year-old female patient with no risk factors for stroke. Cephalalgia. 2006;26(7):894–5.
12. Laurell K, Artto V, Bendtsen L, Hagen K, Kallela M, Meyer EL, etal. Migrainous infarction:
a Nordic multicenter study. Eur J Neurol. 2011;18(10):1220–6.
13. Frigerio R, Santoro P, Ferrarese C, Agostoni E.Migrainous cerebral infarction: case reports.
Neurol Sci. 2004;25(S3):s300–1.
14. Khardenavis V, Karthik DK, Kulkarni S, Deshpande A.Cortical laminar necrosis in a case of
migrainous cerebral infarction. Case Rep. 2018;2018:bcr.
15. Mancini V, Mastria G, Frantellizzi V, Troiani P, Zampatti S, Carboni S, etal. Migrainous infarction in a patient with sporadic hemiplegic migraine and cystic brosis: a 99mTc-HMPAO brain
SPECT study. Headache. 2019;59(2):253–8.
16. Linetsky E, Leker RR, Ben-Hur T. Headache characteristics in patients after migrainous
stroke. Neurology. 2001;57(1):130–2.
17. Serrano F, Arauz A, Uribe R, Becerra LC, Mantilla K, Zermeño F.Long-term follow-up of
patients with migrainous infarction. Clin Neurol Neurosurg. 2018;165:7–9.
18. Censori B, Partziguian T, Poloni M. Migraine improves after ischemic stroke. J Stroke
Cerebrovasc Dis. 2013;22(8):e338–42.
19. Wolf ME, Szabo K, Griebe M, Förster A, Gass A, Hennerici MG, etal. Clinical and MRI characteristics of acute migrainous infarction. Neurology. 2011;76(22):1911–7.
20. Kandemir Yılmaz M, Kirikli P.Bilateral occipital infarcts due to persistent migraine with aura
in an elderly. Agri. 2024;36(4):281–4.
21. Bylund W, Patrick R, Macdonald A.Detection of migrainous infarction with formal visual
eld testing: a case report. Clin Pract Cases Emerg Med. 2020;4(3):366–70.
22. Terrin A, Mainardi F, Maggioni F.The pathological spectrum behind migraine aura status: a
case series. Neurol Sci. 2019;40(4):861–4.
23. Morais R, Sobral F, Cunha G, Brito O, Santana I.Advanced MRI study of migrainous infarction presenting as cortical laminar necrosis—case report and literature review. Clin Neurol
Neurosurg. 2018;167:82–5.
24. Campagna G, Vickers A, Ponce CMP, Lee AG.Homonymous hemianopsia as the presenting
sign of migrainous infarction. Can J Ophthalmol. 2018;53(6):e229–32.
25. Renard D, Nerrant E, Freitag C.Early recurrence of migrainous infarction. Acta Neurol Belg.
2015;115(4):675–6.
26. Lai TH, Hong CT.Prolonged symptoms in sporadic hemiplegic migraine: aura or migrainous
infarction? Acta Neurol Taiwan. 2012;21(3):129–32.
27. Arai S, Utsunomiya H, Arihiro S, Arakawa S.Migrainous infarction in an adult: evaluation with serial diffusion-weighted images and cerebral blood ow studies. Radiat Med.
2008;26(5):313–7.
28. Liang Y, Scott TF.Migrainous infarction with appearance of laminar necrosis on MRI.Clin
Neurol Neurosurg. 2007;109(7):592–6.
33

34
29. Tang SC, Jeng JS, Liu HM, Yip PK.Migrainous infarction involving two different arterial territories: report of two cases. Acta Neurol Taiwan. 2004;13(1):20–3.
30. Arboix A, Massons J, García-Eroles L, Oliveres M, Balcells M, Targa C. Migrainous
cerebral infarction in the Sagrat Cor Hospital of Barcelona stroke registry. Cephalalgia.
2003;23(5):389–94.
31. Sacquegna T, Andreoli A, Baldrati A, Lamieri C, de Carolis P, Pasquale GD, etal. Ischemic
stroke in young adults: the relevance of migrainous infarction. Cephalalgia. 1989;9:255–8.
32. Moen M, Levine SR, Newman DS, Dull-Baird A, Brown GG, Welch KM.Bilateral posterior
cerebral artery strokes in a young migraine sufferer. Stroke. 1988;19(4):525–8.
33. Jacob MA, Ekker MS, Allach Y, Cai M, Aarnio K, Arauz A, etal. Global differences in risk
factors, etiology, and outcome of ischemic stroke in young adults—a worldwide meta- analysis.
Neurology. 2022;98(6):e573–88.
34. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T.Migraine and cardiovascular
disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.
35. Zhao W, Wang D, Tan Y, Yang J, Zhang S.Migraine and the correlation between stroke: a systematic review and meta-analysis. Medicine (Baltimore). 2024;103(45):e40315.
36. Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, etal. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic
review of observational studies. Cephalalgia. 2015;35(2):118–31.
37. Petersen CL, Hougaard A, Gaist D, Hallas J.Risk of stroke and myocardial infarction among
initiators of triptans. JAMA Neurol. 2024;81(3):248.
38. Wang Z, VanderPluym JH, Halker Singh RB, Alsibai RA, Roellinger DL, Firwana M, etal.
Safety of triptans in patients who have or are at high risk for cardiovascular disease. Mayo Clin
Proc. 2024;99(11):1722–31.
39. Nadarajan V, Perry RJ, Johnson J, Werring DJ.Transient ischaemic attacks: mimics and chameleons. Pract Neurol. 2014;14(1):23.
40. Kleindorfer DO, Towghi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D,
etal. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association.
Stroke [Internet]. 2021 [cited 2024 Nov 15];52(7). Available from: https://www.ahajournals.
org/doi/10.1161/STR.0000000000000375.
41. Nguyen AT, Curtis KM, Tepper NK, Kortsmit K, Brittain AW, Snyder EM, etal. U.S. medical eligibility criteria for contraceptive use, 2024. MMWR Recomm Rep. 2024;73(4):1–126.
42. Kurth T, Schürks M, Logroscino G, Buring JE.Migraine frequency and risk of cardiovascular
disease in women. Neurology. 2009;73(8):581–8.
43. Gryglas A, Smigiel R.Migraine and stroke: what’s the link? What to do? Curr Neurol Neurosci
Rep. 2017;17(3):22.
44. Liao CC, Chien CH, Shih YH, Tsai FJ, Li JM.Acupuncture is effective at reducing the risk
of stroke in patients with migraines: a real-world, large-scale cohort study with 19-years of
follow-up. Int J Environ Res Public Health. 2023;20(3):1690.
A. Borrelli et al.

Chapter 4
Migraine Aura-Triggered Seizure
IlariaNotaristefano , ValentinaBaglioni , andVincenzoGuidetti
4.1 Introduction
A migraine aura-triggered seizure, formerly known as migralepsy, is a rare condition characterized by a seizure occurring during or within 1h after a migraine attack
with aura [1]. Lennox and Lennox rst described this condition in their textbook
Epilepsy and Related Disorders, reporting a case of “ophthalmic migraine with perhaps nausea and vomiting followed by symptoms characteristic of epilepsy” [2].
The term migralepsy is a historical portmanteau of migraine and epilepsy,
coined by Dr. Douglas Davidson to describe this phenomenon better. Notably,
such cases are more common in children than in adults [3]. However, due to signicant diagnostic confusion caused by the term migralepsy, it has been replaced
by migraine aura-triggered seizure in more recent classications. The original
term led to misdiagnosis in numerous cases where patients had both migraine with
aura and epilepsy, resulting in an inaccurate classication of their condition.
Additionally, visual migraine aura and occipital seizures can be mistaken for one
another, particularly in cases of prolonged seizures [4]. Although headaches and
seizures are, respectively, the rst and third most common reasons for a referral
from a general practitioner to a neurologist [5], migraine aura-triggered seizure
remains a rare condition [6].
This chapter aims to clarify the nature of this condition, including its characteristics, diagnostic challenges, and key differences from other similar disorders.
I. Notaristefano · V. Baglioni · V. Guidetti (*)
Child and Adolescent Neuropsychiatry, Sapienza University of Rome, Rome, Italy
Switzerland AG 2026
D. Uludüz et al. (eds.), Rare Causes of Headache Disorders, Headache,
https://doi.org/10.1007/978-3-032-10242-3_4
35© The Author(s), under exclusive license to Springer Nature

36
I. Notaristefano et al.
4.2 Pathophysiology
The pathophysiological causes underlying migraine aura-triggered seizures are still
unclear. For this condition to arise, both a migraine aura that induces rapid shifts in
cortical excitability and a brain predisposed to synchronized discharges, as seen in
epilepsy, must be present. Recent research suggests that both migraine and epilepsy
may share a common underlying mechanism of neocortical hyperexcitability,
which—when combined with specic genetic and molecular predispositions—can
lead to distinct downstream phenomena. In epilepsy, this hyperexcitability is
thought to produce a paroxysmal depolarizing shift that directly triggers a seizure,
whereas, in migraine, it evolves into cortical spreading depression (CSD), which is
subsequently followed by cortical suppression [7].
Moreover, the hypothesis that migraine aura may represent a preictal state further unies these observations. According to this view, the neurovascular coupling
mechanisms that underlie the migraine aura—beginning with an initial wave of
hyperexcitability and followed by massive ionic shifts across neuronal membranes—can facilitate seizure onset in a cortex already predisposed to epilepsy.
Essentially, when the rapid changes induced by a migraine aura occur in a brain
susceptible to synchronized discharges, they may pave the way for a seizure [8, 9].
Thus, both hypotheses converge on the idea that a hyperexcitable cortex is central to
the pathogenesis of these conditions. Depending on individual susceptibility and the
dynamics of the underlying neurovascular processes, this hyperexcitability may
manifest as either a migraine with aura, an epileptic seizure, or even a scenario
where the migraine aura itself triggers the seizure.
An alternative hypothesis proposes that aura-triggered seizures represent a form
of reex epilepsy, in which activation of a task-specic neural network induces
excessive neuronal synchronization, ultimately leading to a seizure. However, this
explanation appears less effective in accounting for the observed phenomena [8].
4.3 Case Presentation
An 11-year-old girl has experienced recurrent headaches since she was 4years old.
In her early years, the headaches were relatively mild in severity and accompanied
by nausea and showed improvement with acute treatment with paracetamol. In her
family history, a high frequency of migraine and epileptic conditions was reported:
her mother suffers from migraine with aura and vasculitis, her maternal grandmother has migraine without aura, and an aunt has been diagnosed with epilepsy.
By the age of eight, the patient’s headaches had become more frequent and severe,
prompting a thorough clinical evaluation. She was diagnosed with migraine with
aura following the International Classication of Headache Disorders-III (ICHD-3)
criteria. Her migraine episodes are described as intense, throbbing pain localized to
the right frontal and temporal regions, often accompanied by photophobia,

4 Migraine Aura-Triggered Seizure
phonophobia, facial ushing, and nausea. These attacks occurred approximately
two to four times per month and were disruptive enough to interfere with her daily
activities signicantly. In response to her worsening symptoms, prophylactic treatment with unarizine was started, leading to a notable improvement in her condition. Given the strong family history of migraines, a genetic diagnostic evaluation
was performed by a Next Generation System (NGS) panel to explore potential
inherited causes. However, the genetic investigation revealed no pathogenic variants
among the genes examined. Despite the improvement with unarizine, at the age of
10, the patient experienced 2 distinct episodes where her typical aura was followed
in less than 20min by a sudden loss of consciousness, with a tonic–clonic seizure,
which resolved spontaneously. A similar episode occurred during a subsequent
febrile illness the following year. In light of these seizure episodes, further neurological evaluation was pursued. An interictal electroencephalography (EEG)
revealed the presence of sharp waves, in particular in the centrotemporal regions,
while a brain MRI returned normal ndings.
These investigations led to the initiation of topiramate therapy at a dose of 2mg/
kg/day. More recent EEG assessments have not demonstrated any epileptiform
abnormalities, and, currently, the patient remains free from clinical seizures.
37
4.4 Case Discussion
This clinical case illustrates a migraine aura-triggered seizure, which led to the
young girl’s diagnosis. Several key features can be identied:
1. The presence of migraine with aura symptoms (including throbbing pain, photo-
phobia, phonophobia, facial ushing, and nausea).
2. The occurrence of an epileptic seizure within 1h of the headache onset.
3. A favorable response to antiseizure medication.
4.5 Diagnostic Criteria andDifferential Diagnosis
Per ICHD-3 [1], the diagnosis of migraine aura-triggered seizure is possible in
case of:
A. A seizure fullling diagnostic criteria for one type of epileptic attack, and crite-
rion B below.
B. Occurring in a patient with 1.2 Migraine with aura, and during or within 1h
after an attack of migraine with aura.
C. Not better accounted for by another ICHD-3 diagnosis.
As observed, migraine aura-triggered seizure is a diagnosis of exclusion, meaning that other potential conditions must be ruled out rst. Therefore, it is essential to

38
I. Notaristefano et al.
Table 4.1
Differential features of migraine visual aura and occipital lobe seizures
Migraine visual aura [11] Occipital lobe seizure [12]
Fluttering, uncolored, zigzag
Develops gradually over 5–30min
Acute onset is rare
Total duration <60min
Emerges in the center of the visual eld
and gradually shifts to the outer edges of
a visual hemi-eld, often leaving a blind
spot
Followed by migraine without aura
Spots, circles, and beads with or without
colors may be experienced, but not
dominant
Mainly colored circular patterns
Develop rapidly within seconds
Brief duration (2–3min)
Frequently appear in the outer regions of a temporal
visual hemi-eld, increasing in size and multiplying
during the seizure, often shifting horizontally toward
the opposite side
Postictal headache frequently occurs 3–15min after
the seizures end
Progress to other occipital and extra-occipital
manifestations and convulsions
exclude confounding factors such as visual phenomena of epileptic origin (e.g.,
occipital lobe epilepsy), syncope, and psychogenic non-epileptic seizures (PNES)
[10]. Additionally, for this diagnosis, the association between epileptic seizures and
migraine without aura remains unclear.
In particular, to differentiate visual aura from visual epileptic phenomena, it is
necessary to know their features, as described in Table4.1.
Also, the Visual Aura Rating Scale (VARS) is a validated instrument in which
scores of ±5 are considered indicative of migraine aura [13].
To simplify the approach, a diagnostic algorithm has been proposed for cases
suspected of migraine aura-triggered seizures.
4.6 Diagnostic Algorithm
Step 1: Clinical suspicion.
• Identify key symptoms:
– Migraine with aura (evaluate frequency and intensity).
– Epileptic seizure during or within 1h after an attack of migraine with aura.
Step 2: Initial diagnostic workup.
• Perform EEG, if possible, during migraine.
• Brain imaging.
Step 3: Additional diagnostic evaluations for the differential diagnosis.
• Performed VARS scale.
– Score ≥5 points: probably migraine visual aura.
– Score ≤5 points: improbable migraine visual aura.
• Differential diagnosis from syncope and PNES.

4 Migraine Aura-Triggered Seizure
39
Step 3: Conrm diagnosis.
• Conrm diagnosis of exclusion, considering that it is rarer than the other
conditions.
4.7 Management
Nowadays, there is no specic treatment for migraine aura-triggered seizures. Some
researchers emphasize the importance of preventing migraine onset; however, most
patients respond poorly to traditional migraine treatments such as unarizine and
propranolol [14]. Some evidence suggests that opioids, when used as monotherapy,
may effectively prevent both migraines and subsequent seizures [15]. Other clinicians highlight the strong clinical and EEG response to antiseizure treatment [14],
with the choice of medication depending on the type of seizures presented. Among
available treatments, topiramate has demonstrated efcacy in both migraine and
epilepsy through randomized controlled trials and is approved for both conditions
[16]. For these reasons, it is often the preferred therapeutic option in this context.
4.8 Conclusion
Migraine aura-triggered seizure remains a rare and complex phenomenon at the
intersection of migraine and epilepsy. Despite historical diagnostic confusion surrounding the term “migralepsy,” this condition is now recognized as a diagnosis of
exclusion, requiring careful differentiation from other pathologies. While the underlying mechanisms remain incompletely understood, research suggests that cortical
hyperexcitability plays a central role, with migraine aura potentially acting as a
seizure trigger in predisposed individuals. Management remains challenging, with
conventional migraine prophylaxis often proving insufcient. However, antiseizure
drugs—particularly topiramate—have shown efcacy in reducing both migraine
attacks and seizure occurrence, making them a preferred therapeutic option.
References
1. Headache Classication Committee of the International Headache Society (IHS). The international classication of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. https://
doi.org/10.1177/0333102417738202. PMID: 29368949.
2. Lennox WG.Epilepsy and related disorders. Boston: Little; 1960.
3. Davies PTG, Panayiotopoulos CP. Migraine triggered seizures and epilepsy triggered headache and migraine attacks: a need for re-assessment. J Headache Pain. 2011;12(3):287–8.
https://doi.org/10.1007/s10194- 011- 0344- 2. PMID: 21516466.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
